A Phase III Study to Evaluate the Safety and Immunogenicity of PTX-COVID19-B Administered as Booster Vaccination in Previously Vaccinated Adults Aged 18 Years and Older
Latest Information Update: 27 Oct 2022
At a glance
- Drugs PTX-COVID19-B (Primary) ; Tozinameran
- Indications COVID 2019 infections
- Focus Pharmacodynamics; Registrational
- Sponsors Everest Medicines
Most Recent Events
- 19 Oct 2022 According to an Everest Medicines media release, the company is submitting Investigational New Drug (IND) applications for jointly-conducted phase 3 clinical trials to evaluate PTX-COVID19-B for booster indications.
- 14 Sep 2022 New trial record